SCHEMBL6497788

SCHEMBL6497788

Cc1cc(C(=O)O)c(-c2ccc(F)cc2)cc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.46
BAD Q92934 1/20 0.46
NOTUM Q6P988 1/20 0.45
MCL1 Q07820 2/20 0.45
HSD17B10 Q99714 2/20 0.44
GPR35 Q9HC97 2/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 1/20 0.44
USP2 O75604 1/20 0.44
DHFR P00374 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
LMNA P02545 1/20 0.44
TTR P02766 1/20 0.44
ALB P02768 1/20 0.44
HMGB1 P09429 1/20 0.44
HPGD P15428 1/20 0.44
CXCL12 P48061 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27988934 0.91 BCL2L1 (0.48) BCL2L1BADNOTUMMCL1HSD17B10
SCHEMBL21938180 0.87 BCL2L1 (0.54) BCL2L1BADNOTUMHSD17B10GPR35
SCHEMBL6802081 0.85 MCL1 (0.53) NOTUMMCL1HSD17B10KDM4EALDH1A1
SCHEMBL12149327 0.85 BCL2L1 (0.52) BCL2L1BADNOTUMHSD17B10GPR35
SCHEMBL6500060 0.83 ALDH1A1 (0.51) MCL1ALDH1A1DHFRACMSD
SCHEMBL6497146 0.82 NPC1 (0.53) NOTUMMCL1HSD17B10KDM4EALDH1A1
SCHEMBL24183987 0.81 MCL1 (0.61) MCL1HSD17B10KDM4EALDH1A1MEN1
SCHEMBL6799953 0.81 RXRA (0.55) HSD17B10KDM4EALDH1A1USP2HPGD
SCHEMBL6492370 0.81 HSD17B10 (0.51) BCL2L1BADNOTUMMCL1HSD17B10
SCHEMBL6500578 0.81 HDAC7 (0.51) BCL2L1BADNOTUMMCL1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 BCL2L1 1236/4885BAD 1491/4885NOTUM 840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.